SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.

Shanghai Shyndec Pharmaceutical Co., Ltd.

600420

CNE000001JG2

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2025-07-08			5-day change	1st Jan Change
10.88 ^CNY	+0.18%		+2.16%	-8.88%

07-01	Shyndec Pharmaceutical Unit Gets Registration Certificate for Hypertension Drug in China	MT
06-05	Shyndec Pharmaceutical's Two Drugs Pass Regulatory Evaluation	MT

Shyndec Pharmaceutical Passes Consistency Evaluation for Antibiotic Drug

Published on 2025-04-16 at 04:39, updated on 2025-04-16 at 04:46

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Shanghai Shyndec Pharmaceutical Co., Ltd.

Shyndec Pharmaceutical Unit Gets Registration Certificate for Hypertension Drug in China	07-01	MT
Shyndec Pharmaceutical's Two Drugs Pass Regulatory Evaluation	06-05	MT
Shyndec Pharma Gets Registration Certificate for Hypertension Drug	06-05	MT
Shanghai Shyndec Pharmaceutical Gets Approval for Anti-Tumor Injection	05-29	MT
Shyndec Pharmaceutical Unit's Amikacin Sulfate Injection Passes Regulatory Consistency Evaluation	05-14	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	04-28	CI
Shyndec Pharmaceutical Passes Consistency Evaluation for Antibiotic Drug	04-16	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	03-27	CI
Shyndec Pharmaceutical Subsidiary Passes Generic Drug Consistency Evaluation for Asthma Drug	03-18	MT
Shyndec Pharmaceutical's Unit Gets Registration Certificate for Methylprednisolone Tablets	03-17	MT
Shyndec Pharmaceutical Obtains Registration Certificates for Antiviral, Anticoagulant Drugs	03-10	MT
Shanghai Shyndec Pharmaceutical's Pravastatin Sodium Tablets Passes Chinese Drug Regulator's Consistency Evaluation	03-03	MT
Shyndec Pharma's Units Get Three Drug Registration Certificates	01-22	MT
Shanghai Shyndec's Shenzhen Unit Passes EU GMP Inspection	01-20	MT
Shyndec Pharma Unit's Cefuroxime Sodium for Injection Passes Regulatory Consistency Evaluation	01-20	MT
Shyndec Pharma Gets China Pharmaceutical Ingredient Approval for Anaesthesia Supplementary Drug	01-08	MT
Chinese Drug Regulator Denies Marketing of Shyndec Pharmaceutical's UTI Treatment Drug	01-03	MT
Shanghai Shyndec Pharmaceutical Co., Ltd.(SHSE:600420) added to Shanghai Stock Exchange Health Care Sector Index	12-17	CI
Shanghai Shyndec Pharmaceutical Unit Gets China Nod for Antibiotic Ingredient	12-17	MT
Shyndec Pharmaceutical Unit Gets Nod to Register Cefpodoxime Proxetil Tablets	12-12	MT
Shyndec Pharma Unit's Codeine Phosphate Included in China's Listing of Chemical Raw Materials	12-05	MT
Shanghai Shyndec Pharmaceutical Gets Drug Registration for Eye Drops	12-03	MT
Shanghai Shyndec Pharmaceutical Passes Drug Evaluation for Calcium Gluconate Injection	11-27	MT
Shanghai Shyndec Pharmaceutical CFO Resigns	11-26	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	24-10-28	CI

Chart Shanghai Shyndec Pharmaceutical Co., Ltd.

Duration

Period

Chart Shanghai Shyndec Pharmaceutical Co., Ltd.

600420: Dynamic Chart

SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The Company also offers topical preparations, such as gynecological suppositories and dermatology preparations.

Employees

11,472

Sector

Pharmaceuticals

Calendar

08-29 - Q2 2025 Earnings Release

More about the company